limit catalyst turn around stori
downgrad under-perform lower tp
downgrad under-perform long time bull
follow seri disappoint
move
underwhelm pipelin catalyst see limit driver
upsid move make multipl updat model
includ remov sale follow recent neg fda
advisori committe lower phase data
suggest us limit commerci opportun updat lower
dcf valuat target price lead us
downgrad stock
under-perform
vivitrol aristada unlik carri near-term expect vivitrol
aristada continu gain traction slower consensu current
expect vivitrol sale difficult forecast assum sale
consensu aristada
initio recent approv help initi patient product given
current share trend competit dynam space assum
sale consensu
follow multipl pipelin event expect less newsflow
see addit pipelin news like
complet respons letter jan
submit fda respect potenti
approv month investor also continu
follow data combo keytruda still month away
lower target price model updat lower dcf valuat
target price blend dcf valuat
rel valuat ep go
under-perform rate target price includ commerci surpris
unexpectedli posit data pipelin
main risk
valuat metric
number share
rate outperform under-perform
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
plc global biopharmaceut compani research
develop commerci partner
pharmaceut product design address central
price dec rate outperform under-perform target price analyst vamil
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
grey sky valuat base vivitrol gener
peak sale sale grey sky
valuat base dcf driven wacc along
blue sky valuat base vivitrol
schizophrenia franchis gener peak combin sale sale
blue sky valuat base dcf driven
wacc along termin growth rate thereaft
 close
long time bull stock move under-perform follow
seri disappoint underwhelm pipelin catalyst see limit
driver upsid move
past six week seen fda advisori committe vote
approv key pipelin depress drug call futur drug
question also saw second phase data pipelin schizophrenia drug
studi posit wonder commerci potenti
product given somewhat limit absolut impact drug weight gain six
month fact patient still gain weight final
societi immunotherapi cancer annual meet saw first in-human
data limit conclus could drawn
earli data remov sale model lower peak
sale assumpt two main driver dcf come
target price blend dcf valuat
rel valuat
look forward see lack catalyst drive meaning upsid least
next month figur also believ consensu estim may high
key market product vivitrol aristada result downgrad stock
under-perform wait sign potenti upsid vivitrol aristada and/or
pipelin like compani receiv complet respons letter
jan take month compani meet
fda decid whether product salvag await
regulatori submiss around set stage potenti approv
launch time compani prove us investor wrong
commerci opportun inde robust payer will support product
earli work continu possibl encourag data drug
combin keytruda also expect least lastli
file regul end year set potenti approv
near end head-to-head toler data product tecfidera
could meaning expect econom impact
product limit collabor
addit alreadi model end-market sale
could wrong under-perform rate earli data surpris
upsid especi combin keytruda better seen
date bristol/nektar program
initi subq dose studi
tp base blend dcf valuat rel
valuat dcf base cash flow wacc termin
growth rate roughli line peer rel valuat base market cap
sale multipl year forward sale line group cns-focus
market product vivitrol aristada
unlik drive near-term upsid
debat scale opioid epidem us continu see
vivitrol play import role comprehens approach deal
epidem howev product gener deliv quarterli result in-lin
slightli consensu expect recent quarter figur even
sometim impact inventori fluctuat overal sale
like come near bottom end compani guidanc rang
volum growth product remain robust sale growth lag somewhat
gross-to-net rebat product increas patient drug
medicaid street alreadi expect fairli meaning growth
product figur struggl see upsid come especi
patient start drug medicaid pressur product
us million
figur cs consensu estim vivitrol
us million
compani data credit suiss estim bloomberg profession servic
similarli bullish aristada growth outlook market long-act
inject antipsychot continu grow howev competit dynam market
well price pressur result quarterli aristada sale also
in-lin slightli consensu expect recent quarter figur
compani optimist recent launch aristada initio help get
patient start therapi on-going head-to-head trial aristada vs
sustenna may help increas physician comfort prescrib aristada serv
potenti catalyst acceler growth franchis close follow
growth franchis previous bullish revis estim
somewhat consensu figur
us million
figur cs consensu estim aristada
us million
compani data credit suiss estim bloomberg profession servic
upsid pipelin also like take
two main asset pipelin focus anti-depress
anti-psychot follow setback
fda advisori committe meet remov product model
possibl product may still hold valu even someth
know sever month assum compani receiv complet respons
letter fda action date januari compani
chanc discuss applic fda week follow given
concern fda review advisori committe member regard
product dataset well fact contain opioid would use
chronic out-pati set doubt product salvag
data encourag wonder physician payer
adopt product practic recent releas studi
met co-primari endpoint relat weight gain figur show
differ panss score compar olanzapin six month term
weight gain howev weight gain seen arm studi
absolut differ weight gain lb lb vs lb
olanzapin make challeng messag patient pay
brand therapi may still gain weight less otherwis might
possibl abl commerci effect
current believ know nearli two year given file
product regul approv come also
think unlik investor give addit credit
figur top-line data
mean chang baselin bodi weight month
proport patient gain baselin bodi weight month
proport patient gain baselin bodi weight month
toler safeti
patient complet studi
seriou advers event treatment period
figur cs consensu estim
us million
compani data credit suiss estim bloomberg profession servic
unpredict factor compani pipelin gener
outsiz interest investor despit earli stage develop final
abl review in-human data limit conclus could
drawn earli dataset enrol trial taken longer initi
expect believ data highest dose seven dose escal trial may
avail near end earliest catalyst could drive
increas interest asset could initi data combin merck keytruda
also expect least asset intrigu
consid seen nektar date yet seen suffici
human data justifi incorpor model addit well behind
nektar develop mechan believ could take month
see valid reason increas enthusiasm
beyond asset still work expect
fda submiss file year end encourag highlight
product key strateg prioriti parallel file confirm
second phase studi compar head-to-head gi toler profil
tecfidera would read interim exploratori analysi on-going
singl arm safeti studi indic unexpect safeti find
one year notabl advers gi event discontinu rate
along efficaci brain mri lesion count line would expect
current timelin would set potenti approv late opportun
product surpris upsid howev given collabor
product econom impact limit
alkerm strong histori discov new asset especi
look color compani novel approach may abl
move clinic develop hope gener pipelin valu
target price target price base blend
dcf valuat rel valuat dcf base cash flow
wacc termin growth rate roughli line peer rel
valuat base group market cap sale multipl year forward
sale group consist larg pure compani compani signific
figur blend valuat
figur dcf sensit analysi differ wacc perpetu
charl martineau univers toronto figur market-cap sale multipl
us million
us thousand
us thousand
us thousand unless otherwis state
research develop revenu
amort acquir intang asset
chang fair valu conting consider
average number common share out non-gaap
 sale
sg sale
compani mention price
